Related to MSC-Secreted Factor Key to Impact of Multiple Sclerosis Cell Therapy

• Geron Sidelines Stem Cell Programs and Cuts Workforce to Focus on Clinical Cancer Candidates
  
• Engineered Blood Stem Cells Form Cancer-Killing Lymphocytes In Vivo
  
• Lineagen, Fast Forward Team Up to Develop MS Tests
  
• Genzyme Reports Data from Late-Stage MS Study
  
• FDA Approves Tysabri Label Change and Test for JC Virus Infection in MS Patients
  
• EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS
  
• Sistemic Joins €5.9M TiGenix-Led EU Consortium to Develop Stem Cell Rheumatoid Arthritis Therapy
  
• Endece, MRF to Progress Myelin Regeneration Candidates into Clinic
  
• Cytomedix Picks Up Stem Cell Therapy Firm Aldagen
  
• Fast Forward to Provide Funding for Concert’s MS Spasticity and Pain Candidate
  
• Report Cautions More Drugs, Diagnostics Needed in Europe for Multiple Sclerosis
  
• GW Pharma to Receive $15.7M from Almirall for Expanded Sativex Marketing Rights
  
• Biogen Idec Takes Option to MAKScientific MS Program
  
• Autologous Mesenchymal Stem Cells Found to Aid Kidney Transplant Function
  
• AlloCure Pockets $25M for Acute Kidney Injury Stem Cell Therapy
  
• Medistem Signs On Academic Partners to Study Its Endometrial Regenerative Cell Therapy in TBI
  
• American CryoStem, PGen to Develop Stem Cells for Wound Healing
  
• Engineered HSCs Differentiate into HIV-Specific CTLs that Hold Back HIV Infection In Vivo
  
• Newly Identified Brain MSCs Differentiate Along Mesenchymal, Neuronal Lineages
  
• University of Miami’s Interdisciplinary Stem Cell Institute Awarded $10M